Real-world approaches to preventing acute myeloid leukemia relapse after allogeneic transplantation: a national survey by GITMO (Gruppo Italiano Trapianto Midollo Osseo)
- 5 August 2026
- journal article
- other
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 61 (11) , 1547-1550
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- 2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working PartyBlood, 2026
- Treatment of Acute Myeloid Leukemias and Myelodisplastic Syndromes Relapsing After Allogeneic Stem Cell Transplantation: An In-Depth Analysis of the GITMO AML/MDS-Relapse Registry StudyClinical Lymphoma Myeloma and Leukemia, 2026
- Outcome of Patients With Acute Myeloid Leukemias or Myelodysplastic Syndromes After Relapsing From Allogeneic Stem Cell Transplantation: The GITMO AML / MDS ‐Relapse Registry StudyAmerican Journal of Hematology, 2025
- Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3Journal of Clinical Oncology, 2024
- Azacitidine Post-transplant Maintenance Improves Disease Progression in High-Risk Acute Myeloid Leukemia and Myelodysplastic SyndromeClinical Lymphoma Myeloma and Leukemia, 2024
- A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patientsBlood Advances, 2020
- Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3–Internal Tandem Duplication Mutation (SORMAIN)Journal of Clinical Oncology, 2020
- Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trialThe Lancet Oncology, 2020